« Back
Home /
3-Deazaneplanocin A

3-Deazaneplanocin A

Item no.	HY-10442-100mg
Manufacturer	MedChem Express
CASRN	102052-95-9
Amount	100 mg
Quantity options	100 mg 10mg 1 ea 1 mg 5 mg
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Purity	99.97
Citations	Cancers (Basel). 2022 Jul 23;14(15):3600.<br/>Cell Death Dis. 2020 Oct 23;11(10):906.<br/>Cell Rep. 2023 May 23;42(6):112550.<br/>Cell Reprogram. 2017 Dec;19(6):363-371.<br/>Cells Tissues Organs. 2021 Jan 18;1-9.<br/>Int Immunopharmacol. 2022 Feb 19;106:108612.<br/>J Am Soc Nephrol. 2016 Jul;27(7):2021-34. <br/>J Immunother Cancer. 2019 Nov 14;7(1):300. <br/>J Mol Cell Cardiol. 2019 Oct;135:119-133.<br/>Lab Invest. 2021 Mar 10.<br/>Nat Commun. 2021 Feb 23;12(1):1237.<br/>Patent. US20180263995A1.<br/>Research Square Preprint. 2020 May.<br/>Research Square Print. September 13th, 2022.<br/>Apoptosis. 2020 Oct;25(9-10):697-714.<br/>Biochem Biophys Res Commun. 2018 Sep 10;503(3):2061-2067.<br/>bioRxiv. 2023 Apr 21.<br/>bioRxiv. 2024 May 18.<br/>Cell Signal. 2023 Dec 30:115:111029.<br/>Exp Mol Pathol. 2020 Feb;112:104344.<br/>J Pharmacol Exp Ther. 2019 Sep;370(3):490-503.<br/>Nat Commun. 2022 Jan 10;13(1):12.<br/>Università degli Studi di CAGLIARI. Dipartimento di Scienze Biomediche. 2021 May.<br/>[1]Fiskus W, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood, 2009, 114(13), 2733-2743.<br/>[2]Avan A, et al. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther. 2012 Aug;11(8):1735-46.<br/>[3]Kikuchi J, et al. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer. 2012 Nov;78(2):138-43.<br/>[4]Sun F, et al. Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus?. Eur J Pharm Sci. 2015 Sep 18;77:290-302.<br/>[5]Siddiqi FS, et al. The Histone Methyltransferase Enzyme Enhancer of Zeste Homolog 2 Protects against Podocyte Oxidative Stress and Renal Injury in Diabetes. J Am Soc Nephrol. 2016 Jul;27(7):2021-34.<br/>[6]Noriko Uchiyama, et al. Aristeromycin and DZNeP cause growth inhibition of prostate cancer via induction of mir-26a. Eur J Pharmacol. 2017 Oct 5;812:138-146.<br/>[7]Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52.
Smiles	O[C@@H]1[C@H](O)C(CO)=C[C@H]1N2C=NC3=C2C=CN=C3N
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Alias	DZNep; 3-Deazaneplanocin
Available
Product Description	3-Deazaneplanocin A (DZNep) is a potent histone methyltransferase EZH2 inhibitor[1][2]. 3-Deazaneplanocin A is a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor. 3-Deazaneplanocin A shows anti-orthopoxvirus activity[6][7].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
MolecularWeight	262.26
Clinical Information	No Development Reported
Manufacturers Research Area	Cancer; Infection
Solubility	H2O : 100 mg/mL (ultrasonic)
Target	Histone Methyltransferase; Orthopoxvirus
Manufacturers Target	Histone Methyltransferase; Orthopoxvirus
Isoform	EZH2
Manufacturers Pathway	Anti-infection; Epigenetics
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100 mg

available

Request delivery time